Neurocrine Clinical Site

Boston, Massachusetts 02215

5 studies enrolling now · 12 studies all time

What they study most

Cerebral Palsy, Chorea, Huntington, Congenital Adrenal Hyperplasia, Dyskinesia, Major Depressive Disorder, Schizophrenia, Tourette Syndrome

Studies at this site

• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — Recruiting now
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia — Recruiting now
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease — Completed
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy — Completed
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — Running, not enrolling
• Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease — Completed
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome — Stopped early
• Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed